http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 09:09:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+New+Coverage/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html (Updated - June 16, 2026 9:09 AM EDT) <p>Craig-Hallum analyst Adam Vogel initiates coverage on PepGen Inc. (NASDAQ: PEPG) with a Buy rating and a price target of $11.00.</p><p>The analyst comments "We view PGN-EDODM1 as a high-risk but highly asymmetric myotonic dystrophy type 1 recovery story with the potential for 7-8x upside if higher-dose data validate the early clinical signal. With shares trading at below cash, little-to-no value is being assigned to PEPG’s lead DM1 program, EDO platform optionality, nor the possibility that upcoming clinical data can reframe the story. At current levels, the bar is low enough that cleaner higher-dose http://www.streetinsider.com/Hot+New+Coverage/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html Tue, 16 Jun 2026 09:09:58 -0400 PEPG http://www.streetinsider.com/New+Coverage/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html (Updated - June 16, 2026 9:09 AM EDT) <p>Craig-Hallum analyst Adam Vogel initiates coverage on PepGen Inc. (NASDAQ: PEPG) with a Buy rating and a price target of $11.00.</p><p>The analyst comments "We view PGN-EDODM1 as a high-risk but highly asymmetric myotonic dystrophy type 1 recovery story with the potential for 7-8x upside if higher-dose data validate the early clinical signal. With shares trading at below cash, little-to-no value is being assigned to PEPG’s lead DM1 program, EDO platform optionality, nor the possibility that upcoming clinical data can reframe the story. At current levels, the bar is low enough that cleaner higher-dose http://www.streetinsider.com/New+Coverage/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html Tue, 16 Jun 2026 09:09:58 -0400 PEPG http://www.streetinsider.com/Analyst+Comments/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html (Updated - June 16, 2026 9:09 AM EDT) <p>Craig-Hallum analyst Adam Vogel initiates coverage on PepGen Inc. (NASDAQ: PEPG) with a Buy rating and a price target of $11.00.</p><p>The analyst comments "We view PGN-EDODM1 as a high-risk but highly asymmetric myotonic dystrophy type 1 recovery story with the potential for 7-8x upside if higher-dose data validate the early clinical signal. With shares trading at below cash, little-to-no value is being assigned to PEPG’s lead DM1 program, EDO platform optionality, nor the possibility that upcoming clinical data can reframe the story. At current levels, the bar is low enough that cleaner higher-dose http://www.streetinsider.com/Analyst+Comments/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html Tue, 16 Jun 2026 09:09:58 -0400 PEPG http://www.streetinsider.com/Hot+Comments/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html (Updated - June 16, 2026 9:09 AM EDT) <p>Craig-Hallum analyst Adam Vogel initiates coverage on PepGen Inc. (NASDAQ: PEPG) with a Buy rating and a price target of $11.00.</p><p>The analyst comments "We view PGN-EDODM1 as a high-risk but highly asymmetric myotonic dystrophy type 1 recovery story with the potential for 7-8x upside if higher-dose data validate the early clinical signal. With shares trading at below cash, little-to-no value is being assigned to PEPG’s lead DM1 program, EDO platform optionality, nor the possibility that upcoming clinical data can reframe the story. At current levels, the bar is low enough that cleaner higher-dose http://www.streetinsider.com/Hot+Comments/Craig-Hallum+Starts+PepGen+Inc.+%28PEPG%29+at+Buy%2C+PT+%2411/26650336.html Tue, 16 Jun 2026 09:09:58 -0400 PEPG http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html si-local-file:///var/storage/secattach/20260526/26550769.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html Tue, 26 May 2026 16:44:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html si-local-file:///var/storage/secattach/20260526/26550769.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html Tue, 26 May 2026 16:44:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html si-local-file:///var/storage/secattach/20260522/26538158.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html Fri, 22 May 2026 06:03:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html si-local-file:///var/storage/secattach/20260522/26538158.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html Fri, 22 May 2026 06:03:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html si-local-file:///var/storage/secattach/20260521/26531489.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html Thu, 21 May 2026 07:30:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html si-local-file:///var/storage/secattach/20260521/26531489.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html Thu, 21 May 2026 07:30:00 -0400 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG